Stock Track | Rhythm Pharmaceuticals Soars 6.55% After Beating Q3 2024 Earnings Estimates

Stock Track

2024/11/06

Shares of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) surged 6.55% on Monday, November 5th, after the biopharmaceutical company reported better-than-expected financial results for the third quarter of 2024.

Rhythm Pharmaceuticals announced a quarterly loss of $0.73 per share, beating analysts' consensus estimate of a $0.82 per share loss. The company also reported revenue of $33.251 million, surpassing the average analyst expectation of $32.517 million. Compared to the same period last year, Rhythm's revenue increased by an impressive 47.76%.

The strong Q3 performance highlights the growing demand for Rhythm's products and demonstrates the company's ability to exceed market expectations. Investors reacted positively to the earnings beat, driving RYTM's stock price up by 6.55% on the day of the announcement.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1190694542"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190694542\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190694542?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 05:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190694542","market":"us","top_or_hot":-1,"title":"Stock Track | Rhythm Pharmaceuticals Soars 6.55% After Beating Q3 2024 Earnings Estimates","media":"Stock Track","content":"<p>Shares of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) surged 6.55% on Monday, November 5th, after the biopharmaceutical company reported better-than-expected financial results for the third quarter of 2024.</p>\n\n<p>Rhythm Pharmaceuticals announced a quarterly loss of $0.73 per share, beating analysts' consensus estimate of a $0.82 per share loss. The company also reported revenue of $33.251 million, surpassing the average analyst expectation of $32.517 million. Compared to the same period last year, Rhythm's revenue increased by an impressive 47.76%.</p>\n\n<p>The strong Q3 performance highlights the growing demand for Rhythm's products and demonstrates the company's ability to exceed market expectations. Investors reacted positively to the earnings beat, driving RYTM's stock price up by 6.55% on the day of the announcement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Rhythm Pharmaceuticals Soars 6.55% After Beating Q3 2024 Earnings Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Rhythm Pharmaceuticals Soars 6.55% After Beating Q3 2024 Earnings Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-06 05:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) surged 6.55% on Monday, November 5th, after the biopharmaceutical company reported better-than-expected financial results for the third quarter of 2024.</p>\n\n<p>Rhythm Pharmaceuticals announced a quarterly loss of $0.73 per share, beating analysts' consensus estimate of a $0.82 per share loss. The company also reported revenue of $33.251 million, surpassing the average analyst expectation of $32.517 million. Compared to the same period last year, Rhythm's revenue increased by an impressive 47.76%.</p>\n\n<p>The strong Q3 performance highlights the growing demand for Rhythm's products and demonstrates the company's ability to exceed market expectations. Investors reacted positively to the earnings beat, driving RYTM's stock price up by 6.55% on the day of the announcement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RYTM","symbol_name":"Rhythm Pharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1190694542","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190694542","pubTimestamp":1730841034,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Rhythm Pharmaceuticals Inc.  surged 6.55% on Monday, November 5th, after the biopharmaceutical company reported better-than-expected financial results for the third quarter of 2024.Rhythm Pharmaceuticals announced a quarterly loss of $0.73 per share, beating analysts' consensus estimate of a $0.82 per share loss. The company also reported revenue of $33.251 million, surpassing the average analyst expectation of $32.517 million. Compared to the same period last year, Rhythm's revenue in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RYTM":"Rhythm Pharmaceuticals Inc."},"translate_title":"Rhythm Pharmaceuticals超出2024年第三季度盈利预期后股价飙升6.55%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYTM":1},"content_text":"Shares of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) surged 6.55% on Monday, November 5th, after the biopharmaceutical company reported better-than-expected financial results for the third quarter of 2024.\nRhythm Pharmaceuticals announced a quarterly loss of $0.73 per share, beating analysts' consensus estimate of a $0.82 per share loss. The company also reported revenue of $33.251 million, surpassing the average analyst expectation of $32.517 million. Compared to the same period last year, Rhythm's revenue increased by an impressive 47.76%.\nThe strong Q3 performance highlights the growing demand for Rhythm's products and demonstrates the company's ability to exceed market expectations. Investors reacted positively to the earnings beat, driving RYTM's stock price up by 6.55% on the day of the announcement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}